Share on LinkedInShare on LinkedIn

ARTICLE · 09 DECEMBER 2024

FCA Sets Aside PMPRB's Order That Galderma's Patent Claiming 0.3% Adapalene "Pertained To" 0.1% Adapalene DIFFERIN

On December 3, 2024, the Federal Court of Appeal (FCA) set aside the order of the Patented Medicine Prices Review Board (PMPRB or Board) that had required Galderma to continue to provide information

CanadaIntellectual Property

On December 3, 2024, the Federal Court of Appeal (FCA) set aside the order of the Patented Medicine Prices Review Board (PMPRB or Board) that had required Galderma to continue to provide information to the PMPRB in relation to its 0.1% adapalene product DIFFERIN because of Galderma's Patent No. 2,478,237 (the 237 patent) claiming the use of 0.3% adapalene for the treatment of dermatological disorders: Galderma Canada Inc v Canada (Attorney General), 2024 FCA 208.

As the jurisdiction of the PMPRB only extends to an invention that "pertains to" a medicine, the question on appeal was whether the 237 patent relating to 0.3% adapalene "pertains to" a 0.1% adapalene product (DIFFERIN). The FCA effectively found that the 237 patent did not pertain to DIFFERIN; rather, DIFFERIN was an unpatented medicine.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

See more popular content from